Name

Liminal BioSciences

Legal name

Liminal BioSciences Inc.

Website

https://liminalbiosciences.com

Company type

Private

Founded year

1992

Operating status

Operating

Headcount range

251–500 employees

Ownership category

akta.pro rank

Product category

Clinical-Stage Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD)

Keywords

• Small molecule therapeutics
• GPCR drug discovery
• Clinical-stage biopharmaceuticals
• Metabolic disease pipeline
• Inflammatory disease therapeutics

Headquarters

HQ city

Laval

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Pre-revenue development stage: As a development-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics, Liminal BioSciences does not currently generate revenue from product sales. The company is focused on advancing its lead clinical asset through development and creating value through strategic partnering and/or licensing opportunities. Funding comes from private investment.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

Liminal BioSciences is a development-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that modulate G protein-coupled receptor (GPCR) pathways for the treatment of metabolic, inflammatory and fibrotic diseases. Its lead clinical asset is CBI-6511, a selective GPR84 antagonist being advanced for MASH/MAFLD, and its pipeline also includes a preclinical-stage OXER1 antagonist program targeting eosinophil-driven diseases. Drug discovery operations are conducted through wholly-owned subsidiary Caledon Bioscience.

Product overview

Liminal BioSciences is a development-stage biopharmaceutical company that operates through its wholly-owned subsidiary Caledon Bioscience. The company utilizes a drug discovery platform and data-driven approach to develop novel small molecule therapeutics that modulate G protein-coupled receptor (GPCR) pathways. The pipeline consists of CBI-6511, a clinical-stage selective GPR84 antagonist for MASH/NAFLD metabolic disease, and a preclinical-stage Selective OXER1 Antagonist program targeting eosinophilic-driven inflammatory conditions. The company focuses on first/best-in-class drug candidates for metabolic, inflammatory and fibrotic diseases.

Differentiator

Problem solved

Functional benefit

Brands

• Caledon Bioscience: Wholly-owned subsidiary focused on drug discovery and development of small molecule therapeutics targeting GPCR pathways for metabolic, inflammatory and fibrotic diseases.

Products and services

• CBI-6511 (Selective GPR84 Antagonist) CBI-6511 is Liminal BioSciences' lead clinical-stage asset — a selective, high-potency small molecule antagonist of the medium-chain fatty acid receptor GPR84, in development for the treatment of MASH (Metabolic dysfunction-Associated Steatohepatitis) / NAFLD and related metabolic disease. The compound is intended for once or twice daily oral dosing and has demonstrated preclinical activity in high fat diet models of MASH/MAFLD with reductions in LDL-c and liver steatosis. It has completed Phase 1 SAD/MAD and a 28-day dose-range finding Phase 1b/2a clinical trial, with a Phase IIa study in MASH planned for early 2027.
• Selective OXER1 Antagonist Program The Selective OXER1 Antagonist Program is a preclinical-stage small molecule program targeting the Oxo-eicosanoid receptor 1 (OXER1) for eosinophil-driven inflammatory diseases, with potential indications including asthma, allergic rhinitis, COPD, atopic dermatitis and psoriasis. The program is positioned as potentially first-in-class, with no small molecule OXER1 antagonists currently in clinical development, and may offer a more cost-effective oral alternative to approved biologics for these conditions.
• Caledon Bioscience (Drug Discovery Platform) Caledon Bioscience is the wholly-owned subsidiary of Liminal BioSciences that serves as the company's drug discovery and medicinal chemistry engine. It leverages proprietary expertise in 7TM GPCR biology and medicinal chemistry to design and progress novel small molecule therapeutic candidates, and is the vehicle through which Liminal creates strategic partnering and licensing opportunities for its pipeline.

Quantifiable outcome

• In preclinical experiments, GPR84 antagonists showed activity in high fat diet models of MASH/MAFLD with significant reductions in LDL-c and liver steatosis
• +2 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered core.

• McGill University (Dr. William Powell)coreStrategic or Co-development PartnerThe OXER1 antagonist program is based on the research of Dr. William Powell, Professor Emeritus in the Department of Medicine at McGill University. The research was in-licensed by the company as part of its strategy to develop novel small molecule antagonists of OXER1 for the treatment of eosinophilic-driven diseases.
• Florida Institute of Technology (Dr. Joshua Rokach)coreStrategic or Co-development PartnerThe OXER1 antagonist program was developed in collaboration with Dr. Joshua Rokach of the Florida Institute of Technology. The research collaboration focused on indole-based antagonists such as the lead molecule S-048, which showed good in vitro potency. This research was in-licensed by the company for further development.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Direct peers

• Akero Therapeutics: Akero is developing efruxifermin for MASH and represents a direct competitor in metabolic liver disease. Both companies target the MASH/NASH space with novel mechanism therapies progressing through late-stage clinical trials.
• Madrigal Pharmaceuticals: Madrigal developed Rezdiffra, the first FDA-approved therapy for MASH. Like Liminal, it is pursuing small-molecule therapies for metabolic liver disease, making it the most directly comparable competitor for CBI-6511's lead indication.
• Viking Therapeutics: Viking Therapeutics is a clinical-stage metabolic-focused biopharma with a pipeline targeting obesity, NASH, and metabolic disorders. It is a directly comparable peer in small-molecule metabolic drug development.
• Terns Pharmaceuticals: Terns is a clinical-stage biopharma developing small-molecule therapies for MASH and obesity. It is directly comparable to Liminal as a small-molecule drug developer in metabolic disease.
• Sagimet Biosciences: Sagimet (formerly 3-V Biosciences) is a clinical-stage biopharma developing denifanstat for MASH. It is a directly comparable peer in the small-molecule MASH therapeutic landscape.
• 89bio: 89bio is developing pegozafermin for MASH and other metabolic liver diseases. It is a directly comparable peer operating in the same metabolic disease space with a novel mechanism of action.
• NGM Bio: NGM Bio (now part of Merck) develops biologic and small-molecule therapies for metabolic and liver diseases. It represents a peer in the metabolic disease drug development space with overlapping therapeutic areas.

Broad incumbents

• Intercept Pharmaceuticals: Intercept pioneered the MASH space with obeticholic acid and is a broader incumbent in metabolic liver disease. Comparable as a larger, established player operating in the same therapeutic space.
• Galapagos NV: Galapagos is a clinical-stage biopharma with capabilities in small-molecule drug discovery and development across multiple therapeutic areas. Comparable as a broader specialty pharma with discovery platform capabilities.

Emerging players

• AnaptysBio: AnaptysBio is a clinical-stage biotech developing therapeutics for inflammatory and immune-mediated diseases, including eosinophilic-driven indications. Comparable as a peer addressing similar inflammatory disease pathways.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/liminal-biosciences-inc
• Xx.com/LiminalBio
• Facebookfacebook.com/107266057408064

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds8 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Liminal BioSciences